Paul Haluska

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924
    Paul Haluska
    Department of Oncology, Mayo Clinic, 200 First Street, South West, Rochester, MN 55905, USA
    Mol Cancer Ther 7:2589-98. 2008
  2. pmc Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth
    Marc A Becker
    Corresponding Author Paul Haluska, Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905
    Mol Cancer Ther 12:2909-16. 2013
  3. ncbi request reprint Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
    Paul Haluska
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 13:5834-40. 2007
  4. pmc Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma
    Paul Haluska
    Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 65:765-73. 2010
  5. pmc A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
    Andrea E Wahner Hendrickson
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 124:210-5. 2012
  6. pmc Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer
    Xiaonan Hou
    Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer Res 71:7597-607. 2011
  7. pmc IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors
    Marc A Becker
    Department of Oncology, Mayo Clinic, Rochester, MN, USA
    Clin Cancer Res 18:1808-17. 2012
  8. pmc Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro
    Andrea E Wahner Hendrickson
    Departments of Medicine and Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Res 69:7635-43. 2009
  9. ncbi request reprint In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417
    Paul Haluska
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 66:362-71. 2006
  10. doi request reprint Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors
    Judith A Gilbert
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Endocr Relat Cancer 17:623-36. 2010

Detail Information

Publications27

  1. pmc HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924
    Paul Haluska
    Department of Oncology, Mayo Clinic, 200 First Street, South West, Rochester, MN 55905, USA
    Mol Cancer Ther 7:2589-98. 2008
    ....
  2. pmc Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth
    Marc A Becker
    Corresponding Author Paul Haluska, Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905
    Mol Cancer Ther 12:2909-16. 2013
    ..To this end, we derived a novel HER/VEGF signature that correlated with poor overall survival in high-grade, late stage, serous ovarian cancer patient tumors...
  3. ncbi request reprint Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
    Paul Haluska
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 13:5834-40. 2007
    ..This phase I study was undertaken to define the maximum tolerated dose, safety, and pharmacokinetic profile of CP-751,871...
  4. pmc Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma
    Paul Haluska
    Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 65:765-73. 2010
    ....
  5. pmc A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
    Andrea E Wahner Hendrickson
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Gynecol Oncol 124:210-5. 2012
    ..To assess the effect of tanespimycin on tumor cells, levels of the chaperone proteins HSP90 and HSP70 were examined in peripheral blood mononuclear cells (PBMC) and paired tumor biopsy lysates...
  6. pmc Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer
    Xiaonan Hou
    Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Cancer Res 71:7597-607. 2011
    ..Cooperative cell-cycle arrest, decreased proliferation, and enhanced promotion of apoptosis may contribute to antitumor effects to be gauged in future clinical investigations justified by our findings...
  7. pmc IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors
    Marc A Becker
    Department of Oncology, Mayo Clinic, Rochester, MN, USA
    Clin Cancer Res 18:1808-17. 2012
    ..To improve the significance of insulin-like growth factor-binding protein 5 (IGFBP-5) as a prognostic and potentially predictive marker in patients with breast cancer...
  8. pmc Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro
    Andrea E Wahner Hendrickson
    Departments of Medicine and Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Res 69:7635-43. 2009
    ..Accordingly, further investigation of IGF1R/IR axis as a potential therapeutic target in AML appears warranted...
  9. ncbi request reprint In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417
    Paul Haluska
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 66:362-71. 2006
    ..BMS-554417 is a member of a novel class of IGF-IR/insulin receptor inhibitors that have potential clinical applications because of their antiproliferative and proapoptotic activity in vitro and in vivo...
  10. doi request reprint Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors
    Judith A Gilbert
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Endocr Relat Cancer 17:623-36. 2010
    ..Our results support further research into Hsp90, IGF1R, and EGFR as targets for developing new anticancer therapeutics for some NETs...
  11. pmc Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors
    Alan H Bryce
    Mayo Clinic, Scottsdale, AZ 85255, USA
    Invest New Drugs 30:1934-41. 2012
    ..PK studies revealed no interaction between the drugs. Further investigations of this targeting strategy may be attractive in renal cell carcinoma, non-small cell lung cancer, alveolar sarcoma, and carcinoid tumor...
  12. pmc Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma
    S John Weroha
    Department of Medical Oncology, Mayo, Rochester, MN 55905, USA
    Gynecol Oncol 122:116-20. 2011
    ..We designed a phase II clinical trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small molecule pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan...
  13. ncbi request reprint An organ system based approach to prognosis in advanced melanoma
    Shernan G Holtan
    Department of Medicine, Division of Hematology, Mayo Clinic Graduate School of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Front Biosci (Elite Ed) 4:2823-33. 2012
    ..A subset of melanoma patients appear to lack an organized immune response to the tumor, which portends a poor prognosis...
  14. pmc IGF-1 receptor inhibitors in clinical trials--early lessons
    S John Weroha
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Mammary Gland Biol Neoplasia 13:471-83. 2008
    ..We will also review the completed and ongoing clinical investigations with IGF-1 receptors inhibitors to date and the utility of these early data in designing future breast cancer studies with IGF-1 signaling inhibition strategies...
  15. pmc Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924
    Xiaonan Hou
    Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mol Cancer Ther 10:117-25. 2011
    ..However, pyrrolotriazine IGF-1R/InsR inhibitors do not appear to be affected by this resistance mechanism...
  16. pmc Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors
    Joleen Hubbard
    Division of Medical Oncology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Invest New Drugs 29:473-80. 2011
    ..Levels of the proteins Hsp90, Hsp70 and ILK were measured in peripheral blood mononuclear cell (PMBC) lysates to assess the effects of 17-AAG...
  17. pmc Quantifying insulin receptor isoform expression in FFPE breast tumors
    Sean C Harrington
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States
    Growth Horm IGF Res 22:108-15. 2012
    ..In the present study, qPCR based assays specific for InsR-A, InsR-B and IGF-1R were developed for use in FFPE tissues and tested for feasible use in clinical archived FFPE estrogen receptor (ER)+and ER- breast cancer tumors...
  18. pmc The insulin-like growth factor system in cancer
    S John Weroha
    Department of Oncology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA
    Endocrinol Metab Clin North Am 41:335-50, vi. 2012
    ....
  19. pmc Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents
    Shernan G Holtan
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:985-1000. 2009
    ..The knowledge gained from analyzing similarities and differences between the physiologic state of pregnancy and the pathologic state of cancer could lead to identification of new potential targets for cancer therapeutic agents...
  20. pmc Cixutumumab
    Kevin P McKian
    Mayo Clinic College of Medicine, Division of Medical Oncology, 200 First St SW Rochester, MN 55905, USA
    Expert Opin Investig Drugs 18:1025-33. 2009
    ..In this review, we summarize preclinical, pharmacologic and early clinical data regarding this agent and discuss the impact this drug might have on the future treatment of human cancers...
  21. ncbi request reprint Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy
    Andrea Wahner Hendrickson
    Mayo Clinic College of Medicine, Division of Medical Oncology, Rochester, MN 55905, USA
    Curr Opin Investig Drugs 10:1032-40. 2009
    ....
  22. pmc Tumorgrafts as in vivo surrogates for women with ovarian cancer
    S John Weroha
    Authors Affiliations Departments of Oncology, Radiation Oncology, and Molecular Pharmacology and Experimental Therapeutics Department of Health Sciences Research, Division of Biomedical Statistics and Informatics Division of Gynecologic Surgery Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota and Women s Cancer Program, Samuel Oschin Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California
    Clin Cancer Res 20:1288-97. 2014
    ..Ovarian cancer has a high recurrence and mortality rate. A barrier to improved outcomes includes a lack of accurate models for preclinical testing of novel therapeutics...
  23. pmc Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway
    Catherine J Huntoon
    Division of Oncology Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 70:8642-50. 2010
    ..Taken together, these results identify LATS1 and LATS2 as novel HSP90 clients and show that HSP90 inhibitors can disrupt the LATS tumor suppressor pathway in human cancer cells...
  24. pmc Malignant melanoma in the 21st century: the emerging molecular landscape
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 83:825-46. 2008
    ..We review the emerging molecular landscape of melanoma and its implications for better management of patients with melanoma...
  25. pmc Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells
    Marta Santisteban
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 69:2887-95. 2009
    ..These findings have several important implications related to disease progression and relapse...
  26. ncbi request reprint Complications of therapy and a diagnostic dilemma case. Case 3. Diagnostic dilemma: sarcoidosis simulating metastatic malignancy
    Paul Haluska
    Mayo Clinic, Rochester, MN, USA
    J Clin Oncol 21:4653-4. 2003
  27. ncbi request reprint Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor
    Johann S de Bono
    Royal Marsden NHS Foundation Trust, London, United Kingdom
    Clin Cancer Res 13:3611-6. 2007
    ..To detect insulin-like growth factor-IR (IGF-IR) on circulating tumor cells (CTC) as a biomarker in the clinical development of a monoclonal human antibody, CP-751,871, targeting IGF-IR...